Document is current
Any future updates will be listed below
-
Authors
Ritchlin, Christopher T. https://orcid.org/0000-0002-2602-1219
Coates, Laura C. https://orcid.org/0000-0002-4756-663X
Mease, Philip J. https://orcid.org/0000-0002-6620-0457
van der Heijde, Désirée https://orcid.org/0000-0002-5781-158X
Rahman, Proton https://orcid.org/0000-0002-4521-2029
-
Funding
Funding for this research was provided by:
Johnson & Johnson
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 6 March 2026
First Online: 5 May 2026
Declarations
:
: All authors are members of the APEX Steering Committee. Christopher T Ritchlin received grant/research support from AbbVie, Amgen, and UCB and consulting fees from AbbVie, Amgen, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Pfizer, and UCB. Laura C Coates received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Johnson & Johnson, Moonlake, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Pfizer, and UCB. Dr. Coates is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Philip J Mease received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Inmagene, Johnson & Johnson, Merck, Moonlake, Novartis, Pfizer, Spyre, SUN Pharma, Takeda, and UCB; grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, Sana, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and UCB. Désirée van der Heijde received consulting fees from AbbVie, Alfasigma, ArgenX, Bristol Myers Squibb, Eli Lilly, Grey-Wolf Therapeutics, Johnson & Johnson, Novartis, Pfizer, Takeda, and UCB and is associate editor of Annals Rheumatic Diseases , editorial board member Journal of Rheumatology , and director of Imaging Rheumatology BV. Proton Rahman received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Johnson & Johnson; and research grants from Johnson & Johnson and Novartis.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
